Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

Phototherapeutic keratectomy for map-dot-fingerprint corneal dystrophy.

Cornea 1998 November
PURPOSE: To evaluate the excimer laser as a surgical instrument to treat map-dot-fingerprint (MDF) dystrophies.

METHODS: Thirty eyes (24 patients) with MDF dystrophy were treated with phototherapeutic keratectomy (PTK). The treatment goal was either to improve vision (24 eyes) or to heal recurrent corneal erosions or both (10 eyes). Besides long-standing reduction in visual acuity (17 eyes), associated symptoms were fluctuating visual acuity and clinical refraction (12 eyes) and monocular diplopia (eight eyes). In 14 eyes, two or three symptoms were present, whereas 16 eyes only had one symptom. The mean age was 54 years (range, 36-79 years), and there were 14 male and 10 female subjects. Mean follow-up was 30 months (range, 12-70 months).

RESULTS: In 14 of 17 eyes with long-standing reduction in visual acuity, best spectacle-corrected Snellen visual acuity (BSCVA) improved by two lines or more. All eyes with fluctuating visual acuity/clinical refraction stabilized 1-3 months after PTK. Monocular diplopia or "ghost images" disappeared in all eyes after treatment. In one of 10 eyes with recurrent corneal erosions, there was one recurrence during the follow-up period. All eyes healed shortly after treatment. No recurrence of corneal dystrophic changes was seen in the ablation zone at the final follow-up (mean, 30 months). Dystrophic changes could, however, still be seen outside the treatment zone in 50% of the eyes, but were asymptomatic in all eyes. The mean refractive change was 0.34 +/- 1.05 (mean +/- SD) diopters.

CONCLUSION: In this study, excimer laser photoablation was shown to be an effective, safe, and stable choice of treatment for map-dot-fingerprint dystrophy. A refractive change, as hyperopic shift, can be an adverse side effect in some individual cases.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app